InpharmD™





One touch literature search.

So you can spend more time with patients

Ask any clinical question, receive a curated response.

Get Started Free

Trusted by 20,000+ physicians, nurse practitioners, physician assistants, and pharmacists.

                 

Play Circle

Learn about InpharmD™ in under 90 seconds

What is InpharmD™?


Literature searching is tedious. InpharmD™ is here to help.

Clinical pharmacists can ask any question, anytime, from anywhere, and we’ll perform a custom literature search.

(And a 32% chance it’s already been asked.)


25,966

Clinical Pharmacist Hours Saved

4x +

ROI

100%

Customer Satisfaction Rate

This is how InpharmD™ transforms LITERATURE.

What's Being Asked...

What are the therapeutic alternatives for Azacitidine Injection?
Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma
Can piperacillin and tazobactam (Zosyn) be infused with Lactated Ringers?
what are the therapeutic alternatives for the new drug 50% & 60*2 (MFR >12) and (GDF/20) pottasium (100mg/ml)?
Exploring the links between gut microbiota and excitatory and inhibitory brain processes in alcohol use disorder: A T...

What would you like to ask InpharmD™?

InpharmD's Answer GPT's Answer

Author:gabrielle pak, PharmD, BCPS + InpharmD™ AI

INTRODUCTION BY INPHARMD™ RESEARCHER

5-Azacytidine is a pyrimidine nucleoside analog that has been discovered more than 40 years ago. Despite remarkable responses in the treatment of acute myeloid leukemias in the 1970s no earlier than 2004 has this agent been approved by the US FDA for the treatment of all subtypes of myelodysplatic syndromes (MDS). For the first time a drug was proven to alter the natural course of MDS, as demonstrated in three clinical trials conducted by the CALG B. Complete remission rates ranged between 10...

5-Azacytidine is a pyrimidine nucleoside analog of cytidine that undergoes incorporation into DNA and blocks DNA methyltransferase leading to hypomethylation and potentially beneficial re-expression of abnormally silenced genes. It is the first agent approved for use in patients with myelodysplastic syndromes (MDSs) based on its improvement in overall survival as monotherapy. Evidence of efficacy in combination with other agents is also accumulating. Our understanding of the molecular basis and pathogenesis of MDS continues to evolve rapidly. 5-Azacytidine has been shown to improve both overall survival and quality of life in patients with high-risk MDS. Currently, the oral route of administration is undergoing evaluation in clinical trials. Used as a monotherapy and also in novel combinations, 5-azacytidine has the potential to further improve the prognosis of some patients with MDS. [1] Azacitidine is the first drug in a new class of compounds, known as DNA hypomethylating agent...

READ MORE→

A search of the published medical literature revealed 1 study investigating the researchable question:

What are the therapeutic alternatives for Azacitidine Injection?

Level of evidence
C - Multiple studies with limitations or conflicting results  

READ MORE→

[1] Choi M, Song J, Bui CN, Ma E, Chai X, Yin L, Betts KA, Kapustyan T, Montez M, LeBlanc TW. J Manag Care Spec Pharm. 2022 Sep;28(9):980-988. doi: 10.18553/jmcp.2022.22021. Epub 2022 Jun 16.
[2] Müller A, Florek M. Recent Results Cancer Res. 2010;184:159-70. doi: 10.1007/978-3-642-01222-8_11.
[3] Sullivan M, Hahn K, Kolesar JM. Am J Health Syst Pharm. 2005 Aug 1;62(15):1567-73. doi: 10.2146/ajhp040385.
[4] Issa JP, Kantarjian HM, Kirkpatrick P. Nat Rev Drug Discov. 2005 Apr;4(4):275-6. doi: 10.1038/nrd1698.

InpharmD's Answer GPT's Answer

Author:Neil Patel, PharmD, BCPS + InpharmD™ AI

INTRODUCTION BY INPHARMD™ RESEARCHER

Measurable residual disease (MRD) is a major prognostic factor in newly diagnosed multiple myeloma. An assessment of an MRD-guided consolidation strategy in patients who are eligible for autologous stem-cell transplantation (ASCT) may be useful. Methods: In this phase 3 trial, we randomly assigned transplantation-eligible patients with newly diagnosed myeloma who had completed induction therapy with isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) to receive consolidatio...

Measurable residual disease (MRD) is a major prognostic factor in newly diagnosed multiple myeloma. An assessment of an MRD-guided consolidation strategy in patients who are eligible for autologous stem-cell transplantation (ASCT) may be useful. Methods: In this phase 3 trial, we randomly assigned transplantation-eligible patients with newly diagnosed myeloma who had completed induction therapy with isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) to receive consolidation therapy according to their MRD status. Patients who were MRD-negative at 10-5 sensitivity (i.e., <1 cancer cell per 100,000 normal cells, as assessed by next-generation sequencing were assigned to undergo ASCT and receive Isa-KRd for two cycles (ASCT group) or to receive Isa-KRd for six cycles (Isa-KRd group). Patients who were MRD-positive at 10-5 sensitivity were assigned to undergo tandem ASCT (two ASCTs within a short period; tandem ASCT group) or to undergo ASCT and receive Isa-KRd for tw...

READ MORE→

A search of the published medical literature revealed 1 study investigating the researchable question:

Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma

Level of evidence
B - One high-quality study or multiple studies with limitations  

READ MORE→

InpharmD's Answer GPT's Answer

Author:gabrielle pak, PharmD, BCPS + InpharmD™ AI

INTRODUCTION BY INPHARMD™ RESEARCHER

​​The manufacturer of Zosyn states Lactated Ringer's Solution is compatible only with reformulated Zosyn containing EDTA and is compatible with co-administration via a Y-site. Trissel's IV compatibility database notes the older formulation without the added components (most generic products) is incompatible with Lactated Ringer's. Thus, the newer formulation is the only form of the drug mixed with this diluent. A study that tested the physical compatibility of Lactated Ringer's found compatib...

Wyeth, the manufacturer of Zosyn, states Lactated Ringer's Solution is compatible only with reformulated Zosyn containing EDTA and is compatible with co-administration via a Y-site. Many generic formulations (e.g., Apotex) do not contain EDTA. [1, 2] Trissel's IV compatibility database notes the older formulation without the added components (most generic products) is incompatible with Lactated Ringer's. Ensure that the newer formulation is the only form of the drug mixed with Lactated Ringer's. [3] A 2019 study that tested the physical compatibility of Lactated Ringer's with 94 medications found incompatibilities with ciprofloxacin, cyclosporine, diazepam, ketamine, lorazepam, nitroglycerin, phenytoin, and propofol after 4 hours at room temperature. This study surprisingly found compatibility with ceftriaxone, amphotericin B, and piperacillin-tazobactam, which all previously were thought to be incompatible with LR (See Tables 1 and 2). [4] The study utilized a formulation of...

READ MORE→

A search of the published medical literature revealed 2 studies investigating the researchable question:

Can piperacillin and tazobactam (Zosyn) be infused with Lactated Ringers?

Level of evidence
B - One high-quality study or multiple studies with limitations  

READ MORE→

[1] ZOSYN IN GALAXY CONTAINERS (tazobactam sodium and piperacillin sodium injection, solution). Prescribing information. Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.; 2023.
[2] PIPERACILLIN AND TAZOBACTAM injection, powder, for solution. Prescribing information. Apotex Corp.; 2024.
[3] Zosyn in LR Trissel's IV Compatibility [Database] Lexicomp. Available from: https://online.lexi.com/lco/action/ivcompatibility/trissels. Accessed May 14, 2024.
[4] Vallée M, Barthélémy I, Friciu M, et al. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Si...

InpharmD's Answer GPT's Answer

Author:gabrielle pak, PharmD, BCPS + InpharmD™ AI

INTRODUCTION BY INPHARMD™ RESEARCHER

Inflammatory bowel disease (IBD), a chronic immune disorder, has increasing global incidence and poor treatment outcome. Abnormal macrophage function is implicated in the pathophysiology of IBD. In this study, we investigated the mechanism by which human umbilical cord mesenchymal stem cell-derived exosomes (hucMSC-Ex) inhibit inflammation in IBD mouse and macrophage inflammation models.

We established a dextran sodium sulfate (DSS)-induce BALB/c mice model of IBD and treated with hucMSC-Ex via tail vein to evaluate their repair effect on IBD mice. An in vitro macrophage inflammation model was established using lipopolysaccharide (LPS) and Nigericin (Nig) by stimulating mouse macrophage RAW264.7 and human myeloid leukemia mononuclear (THP-1) cells to assess the repair effect of hucMSC-Ex on macrophage inflammation. EX 527, an effective inhibitor of silent information regulator of transcription 1 (SIRT1), was employed in both the in vivo and in vitro models to explore the effect of hucMSC-Ex on the SIRT1-FXR (farnesoid X receptor) pathway in macrophages during the attenuation of inflammation. HucMSC-Ex effectively inhibited inflammation in both the in vivo and in vitro models by up-regulating the expressions of SIRT1 and FXR, which reduced the acetylation level of FXR and inhibited the activation of NOD-like receptor thermal protein domain associated protein 3 (NLR...

READ MORE→

A search of the published medical literature revealed 1 study investigating the researchable question:

What are the therapeutic alternatives for the antiepileptic drug 50% & 60*2 (MFR >12) and (GDF/20) pottasium (100mg/ml)?

Level of evidence
B - One high-quality study or multiple studies with limitations  

READ MORE→

InpharmD's Answer GPT's Answer

Author:Chinnarao Sana, PharmD, BCPS + InpharmD™ AI

INTRODUCTION BY INPHARMD™ RESEARCHER

While the impact of the gut microbiota on brain and behavior is increasingly recognized, human studies examining this question are still scarce. The primary objective of the current study was to explore the potential relationships between the gut microbiota composition, motor cortical excitability at rest and during inhibitory control, as well as behavioral inhibition, in healthy volunteers and in patients suffering from alcohol use disorder. Motor cortical excitability was examined using a r...

Moreover, TMS was applied during a choice reaction time task to assess changes in motor excitability associated with inhibitory control. Finally, behavioral inhibition was investigated using a neuropsychological task (anti-saccade). Overall, our results highlight several interesting correlations between microbial composition and brain measures. Hence, higher bacterial diversity, as well as higher relative abundances of UGC-002 and Christensenellaceae R-7 group were correlated with stronger changes in motor excitability associated with inhibitory control. Also, higher abundance of Anaerostipes was associated with higher level of corticospinal excitability. Finally, relative abundances of Bifidobacterium and Faecalibacterium were positively related to performance in the neuropsychological task, suggesting that they might have a positive impact on behavioral inhibition. Although correlation is not causation, the present study suggests that excitatory and inhibitory brain processes migh...

READ MORE→

A search of the published medical literature revealed 1 study investigating the researchable question:

Exploring the links between gut microbiota and excitatory and inhibitory brain processes in alcohol use disorder: A TMS study

Level of evidence
C - Multiple studies with limitations or conflicting results  

READ MORE→

Find answers, not documents.

Before InpharmD™


BeforeTime
Your team spends hours per week cobbling together literature from different studies, many behind paywalls, leaving little time for action.
BeforeTime
TI opportunities are discovered (or presented by third parties) months after the fact, resulting in costly missed savings.
BeforeTime
Decisions may be made without a complete picture, or pushed out while gathering consensus.

After InpharmD™


BeforeTime
InpharmD™ delivers customized, actionable drug information in real time, so you can focus on execution.
BeforeTime
Your team stays informed immediately when new data emerges or prices change, and you’ll always be the first to know when any changes impact your formulary.
BeforeTime
With InpharmD™, your team can make faster, more informed decisions and move forward with confidence.

What Clinical Pharmacists Are Saying...


     

Assists in our research and is a great way or us to get an answer to a medical question without spending an average of 2 hours researching UptoDate or PubMed ourselves.


  Jordan C., PharmD, New Jersey

     

Huge time saver with thorough responses.


  Jane D., PharmD, Georgia

     

I’d never heard of a DI pharmacist before, now I have one. In. My. Pocket. Amazing!


     

Holy Shhh. Cow! Holy Cow! These summaries are beautiful.


  Jane D., PharmD, Georgia

     

I just want to say: This is such a brilliant idea! You people are genius.


     

OH MY GOD WHERE HAVE YOU BEEN ALL MY LIFE!


     

I can’t tell you how much time I spend literature searching. And how I CANNOT STAND PAYWALLS. THIS IS UNBELIEVABLE!! (covers face for sec) thank you, thank you, thank you!


     

So they’re basically connecting academic researchers with front line providers and then automating everything. It’s simply brilliant.


     

The clinical pharmacist was our secret weapon anyway. (Smiles wryly) This pharmacist AI seems superhuman. I’m just blown away, honestly. (Looks at camera somberly.)


     

It’s an ENTIRE DI DEPARTMENT, that lives in Epic. Give me a second. I’m just having a hard time wrapping my head around that.


     

Sorry just give me a second, my mind is blown.


     

Stop reading and just download the app already! I’ve tried all of them. This is by far the most advanced, best-in-class.


What would you like to ask InpharmD™?

Sign up for a free trial & start right away.

Get Started Free